Private Advisor Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-10,355
| Closed | -$113K | – | 2225 |
|
|
2023
Q3 | $113K | Sell |
10,355
-2,600
| -20% | -$28.5K | ﹤0.01% | 1924 |
|
|
2023
Q2 | $167K | Buy |
12,955
+700
| +6% | +$9.04K | ﹤0.01% | 1871 |
|
|
2023
Q1 | $147K | Sell |
12,255
-500
| -4% | -$6K | ﹤0.01% | 1828 |
|
|
2022
Q4 | $175 | Sell |
12,755
-2,370
| -16% | -$33 | ﹤0.01% | 1529 |
|
|
2022
Q3 | $222K | Sell |
15,125
-9,150
| -38% | -$134K | ﹤0.01% | 1626 |
|
|
2022
Q2 | $369K | Buy |
24,275
+1,850
| +8% | +$28.1K | ﹤0.01% | 1545 |
|
|
2022
Q1 | $404K | Buy |
22,425
+610
| +3% | +$11K | ﹤0.01% | 1521 |
|
|
2021
Q4 | $519K | Buy |
21,815
+1,400
| +7% | +$33.3K | ﹤0.01% | 1428 |
|
|
2021
Q3 | $620K | Hold |
20,415
| – | – | ﹤0.01% | 1405 |
|
|
2021
Q2 | $651K | Buy |
20,415
+494
| +2% | +$15.8K | 0.01% | 1266 |
|
|
2021
Q1 | $596K | Sell |
19,921
-744
| -4% | -$22.3K | 0.01% | 1219 |
|
|
2020
Q4 | $655K | Sell |
20,665
-600
| -3% | -$19K | 0.01% | 1092 |
|
|
2020
Q3 | $584K | Buy |
21,265
+230
| +1% | +$6.32K | 0.01% | 994 |
|
|
2020
Q2 | $570K | Sell |
21,035
-3,220
| -13% | -$87.3K | 0.01% | 968 |
|
|
2020
Q1 | $474K | Buy |
24,255
+2,770
| +13% | +$54.1K | 0.01% | 914 |
|
|
2019
Q4 | $504K | Sell |
21,485
-760
| -3% | -$17.8K | 0.01% | 1044 |
|
|
2019
Q3 | $417K | Buy |
22,245
+345
| +2% | +$6.47K | 0.01% | 1131 |
|
|
2019
Q2 | $462K | Sell |
21,900
-2,235
| -9% | -$47.1K | 0.01% | 1084 |
|
|
2019
Q1 | $507K | Buy |
24,135
+4,950
| +26% | +$104K | 0.01% | 963 |
|
|
2018
Q4 | $362K | Buy |
19,185
+4,050
| +27% | +$76.4K | 0.01% | 955 |
|
|
2018
Q3 | $376K | Buy |
+15,135
| New | +$376K | 0.01% | 1116 |
|